Like petroleum, steel, automobile and consumer goods several decades ago, the biopharmaceutical industry is currently considering a wider implementation of continuous processing as part of a global process intensification objective.

Justifications for switching from batch to continuous chromatography are numerous. Besides, the rising demand for biologics suggests
- reduced processing and labor costs,
- footprint reduction,
- flexibility increase,
- more stringent requirements for controlled,
- more consistent and improved quality;
- finally and most importantly, the requirement for higher productivity and therefore overall manufacturing cost reduction.

Last but not least regulators are pushing for continuous processing.

Join Thomas Flouquet and Jérôme Chevalier for this webinar and discover how BioSC™ Pilot can turn your Downstream process continuous.